Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 4:26 pm Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,913,005 4.920% | 34,709 (+1.21%) | Filing History |
| 2024-02-06 4:15 pm Purchase | 2023-12-31 | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,878,296 6.800% | 1,735 (+0.06%) | Filing History |
| 2023-03-03 4:30 pm Purchase | 2021-03-16 | 13D | Marker Therapeutics, Inc. MRKR | Aisling Capital IV LP | 464,285 5.460% | 464,285 (New Position) | Filing History |
| 2023-02-08 5:00 pm Purchase | 2022-12-31 | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,876,561 12.340% | 10,413 (+0.36%) | Filing History |
| 2022-02-14 12:16 pm Purchase | 2021-12-31 | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,866,148 12.330% | 2,866,148 (New Position) | Filing History |
| 2022-02-14 12:14 pm Purchase | 2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | Aisling Capital IV LP | 288,571 0.770% | 288,571 (New Position) | Filing History |